Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: a Children's Oncology Group study
- PMID: 16435380
- DOI: 10.1002/pbc.20739
Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: a Children's Oncology Group study
Abstract
Purpose: The Children's Oncology Group conducted a phase II trial of 21-day continuous infusion topotecan to determine the response rate in pediatric patients with recurrent or refractory malignant solid tumors.
Procedure: Patients with Ewing sarcoma family of tumors (ESFT), osteosarcoma (OS), soft tissue sarcomas (STS), medulloblastoma (MB)/primitive neuroectodermal tumor (PNET), astrocytoma, or neuroblastoma (NB) recurrent or refractory to conventional therapy, measurable disease, and adequate organ function were treated with topotecan 0.3 mg/m2/day by continuous intravenous infusion for 21 consecutive days, followed by 7 days without therapy prior to response assessment.
Results: Fifty-five patients were enrolled; two were ineligible, two were removed from protocol therapy prior to evaluation for response, and one was inevaluable for response, leaving 53 and 50 patients evaluable for toxicity and response, respectively. Objective responses were seen in 2/20 patients with ESFT (both partial responses, 4 and 19 courses), 0/10 OS patients, and 0/12 STS patients. There were insufficient patients enrolled to determine the response rate for the MB/PNET, astrocytoma, and NB strata. The most common Grade 3 or 4 toxicities during the first course of therapy were thrombocytopenia (12/53), neutropenia (8/53), and fatigue (7/53).
Conclusion: Intravenous topotecan by 21-day continuous infusion is tolerable in pediatric patients with recurrent or refractory solid tumors. Limited activity was seen in ESFT and further development of this topotecan schedule as a single agent is not warranted.
(c) 2006 Wiley-Liss, Inc.
Similar articles
-
Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study.Clin Cancer Res. 1998 Feb;4(2):357-60. Clin Cancer Res. 1998. PMID: 9516923 Clinical Trial.
-
Phase I study of topotecan administered as a 21-day continous infusion in children with recurrent solid tumors: a report from the Children's Cancer Group.Clin Cancer Res. 1999 Dec;5(12):3956-62. Clin Cancer Res. 1999. PMID: 10632325 Clinical Trial.
-
A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study.Pediatr Blood Cancer. 2008 Feb;50(2):254-8. doi: 10.1002/pbc.21132. Pediatr Blood Cancer. 2008. PMID: 17262795 Clinical Trial.
-
Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: an integrated analysis.Oncologist. 2005 Oct;10(9):686-94. doi: 10.1634/theoncologist.10-9-686. Oncologist. 2005. PMID: 16249347 Review.
-
New drugs for the treatment of metastatic or refractory soft tissue sarcomas in children.Future Oncol. 2006 Oct;2(5):675-85. doi: 10.2217/14796694.2.5.675. Future Oncol. 2006. PMID: 17026459 Review.
Cited by
-
YM155 and chrysin cooperatively suppress survivin expression in SMARCB1/INI1-deficient tumor cells.Med Oncol. 2022 Sep 29;39(12):234. doi: 10.1007/s12032-022-01843-4. Med Oncol. 2022. PMID: 36175806
-
Comparative characteristics of small cell lung cancer and Ewing's sarcoma: a narrative review.Transl Lung Cancer Res. 2022 Jun;11(6):1185-1198. doi: 10.21037/tlcr-22-58. Transl Lung Cancer Res. 2022. PMID: 35832443 Free PMC article. Review.
-
Reply to J.-G. Wang et al.J Clin Oncol. 2022 May 1;40(13):1507-1508. doi: 10.1200/JCO.21.02922. Epub 2022 Mar 2. J Clin Oncol. 2022. PMID: 35235382 Free PMC article. No abstract available.
-
Outcome of patients with relapsed or progressive Ewing sarcoma enrolled on cooperative group phase 2 clinical trials: A report from the Children's Oncology Group.Pediatr Blood Cancer. 2021 Dec;68(12):e29333. doi: 10.1002/pbc.29333. Epub 2021 Sep 8. Pediatr Blood Cancer. 2021. PMID: 34496122 Free PMC article. Clinical Trial.
-
Ewing Sarcoma-Diagnosis, Treatment, Clinical Challenges and Future Perspectives.J Clin Med. 2021 Apr 14;10(8):1685. doi: 10.3390/jcm10081685. J Clin Med. 2021. PMID: 33919988 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous